Drug metabolites as cytochrome P450 inhibitors: A retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development

Drug Metabolism and Disposition

Volumn 41, Issue 12, 2013, Pages 2047-2055

  Callegari, Ernesto ^a   Kalgutkar, Amit S ^a   Leung, Louis ^a   Obach, R Scott ^a   Plowchalk, David R ^a   Tse, Susanna ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 INHIBITOR; DRUG METABOLITE;

AREA UNDER THE CURVE; ARTICLE; DRUG DEVELOPMENT; DRUG EXPOSURE; DRUG INTERACTION; DRUG POTENCY; DRUG RESEARCH; DRUG TRANSFORMATION; ENZYME INHIBITION; HUMAN; IN VITRO STUDY; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ALGORITHMS; AREA UNDER CURVE; BIOTRANSFORMATION; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG DISCOVERY; DRUG INTERACTIONS; HUMANS; PHARMACEUTICAL PREPARATIONS; RETROSPECTIVE STUDIES;

EID: 84888583720     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.113.052241     Document Type: Article

References (35)

1. Anderson S, Knadler MP, and Luffer-Atlas D (2010) Overview of metabolite safety testing from an industry perspective. Bioanalysis 2:1249-1261.
2. Backman JT, Kyrklund C, Neuvonen M, and Neuvonen PJ (2002) Gemfibrozil greatly increases plasma concentrations of cerivastatin. Clin Pharmacol Ther 72:685-691.
3. Baer BR, DeLisle RK, and Allen A (2009) Benzylic oxidation of gemfibrozil-1-O-beta-glucuronide by P450 2C8 leads to heme alkylation and irreversible inhibition. Chem Res Toxicol 22:1298-1309.
4. Chenel M, Bouzom F, Cazade F, Ogungbenro K, Aarons L, and Mentré F (2008) Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 2: clinical trial results. J Pharmacokinet Pharmacodyn 35:661-681.
5. Cheng YC and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
6. Fahmi OA, Hurst S, Plowchalk D, Cook J, Guo F, Youdim K, Dickins M, Phipps A, Darekar A, and Hyland R, et al. (2009) Comparison of different algorithms for predicting clinical drug-drug interactions, based on the use of CYP3A4 in vitro data: predictions of compounds as precipitants of interaction. Drug Metab Dispos 37:1658-1666.
7. Fenneteau F, Poulin P, and Nekka F (2010) Physiologically based predictions of the impact of inhibition of intestinal and hepatic metabolism on human pharmacokinetics of CYP3A substrates. J Pharm Sci 99:486-514.
8. Honkalammi J, Niemi M, Neuvonen PJ, and Backman JT (2011) Mechanism-based inactivation of CYP2C8 by gemfibrozil occurs rapidly in humans. Clin Pharmacol Ther 89:579-586.
9. Isoherranen N, Hachad H, Yeung CK, and Levy RH (2009) Qualitative analysis of the role of metabolites in inhibitory drug-drug interactions: literature evaluation based on the metabolism and transport drug interaction database. Chem Res Toxicol 22:294-298.
10. Jenkins SM, Zvyaga T, Johnson SR, Hurley J, Wagner A, Burrell R, Turley W, Leet JE, Philip T, and Rodrigues AD (2011) Studies to further investigate the inhibition of human liver microsomal CYP2C8 by the acyl-β-glucuronide of gemfibrozil. Drug Metab Dispos 39:2421-2430.
11. Jones HM, Dickins M, Youdim K, Gosset JR, Attkins NJ, Hay TL, Gurrell IK, Logan YR, Bungay PJ, and Jones BC, et al. (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42:94-106.
12. Kotlyar M, Brauer LH, Tracy TS, Hatsukami DK, Harris J, Bronars CA, and Adson DE (2005) Inhibition of CYP2D6 activity by bupropion. J Clin Psychopharmacol 25:226-229.
13. Kudo T, Hisaka A, Sugiyama Y, and Ito K (2013) Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes. Drug Metab Dispos 41:362-371.
14. Leclercq L, Cuyckens F, Mannens GS, de Vries R, Timmerman P, and Evans DC (2009) Which human metabolites have we MIST? Retrospective analysis, practical aspects, and perspectives for metabolite identification and quantification in pharmaceutical development. Chem Res Toxicol 22:280-293.
15. Lutz JD and Isoherranen N (2012) Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab Dispos 40:159-168.
16. Mori K, Hashimoto H, Takatsu H, Tsuda-Tsukimoto M, and Kume T (2009) Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development. Xenobiotica 39:415-422.
17. Obach RS, Walsky RL, Venkatakrishnan K, Houston JB, and Tremaine LM (2005) In vitro cytochrome P450 inhibition data and the prediction of drug-drug interactions: qualitative relationships, quantitative predictions, and the rank-order approach. Clin Pharmacol Ther 78:582-592.
18. Ogilvie BW, Zhang D, Li W, Rodrigues AD, Gipson AE, Holsapple J, Toren P, and Parkinson A (2006) Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions. Drug Metab Dispos 34:191-197.
19. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, and Yokoi T (2000) Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244-253.
20. Orr STM, Ripp SL, Ballard TE, Henderson JL, Scott DO, Obach RS, Sun H, and Kalgutkar AS (2012) Mechanism-based inactivation (MBI) of cytochrome P450 enzymes: structure-activity relationships and discovery strategies to mitigate drug-drug interaction risks. J Med Chem 55:4896-4933.
21. Perdaems N, Blasco H, Vinson C, Chenel M, Whalley S, Cazade F, and Bouzom F (2010) Predictions of metabolic drug-drug interactions using physiologically based modelling: Two cytochrome P450 3A4 substrates coadministered with ketoconazole or verapamil. Clin Pharmacokinet 49:239-258.
22. Pollock BG, Sweet RA, Kirshner M, and Reynolds CF, 3rd (1996) Bupropion plasma levels and CYP2D6 phenotype. Ther Drug Monit 18:581-585.
23. Reese MJ, Wurm RM, Muir KT, Generaux GT, St John-Williams L, and McConn DJ (2008) An in vitro mechanistic study to elucidate the desipramine/bupropion clinical drug-drug interaction. Drug Metab Dispos 36:1198-1201.
24. Schroeder DH (1983) Metabolism and kinetics of bupropion. J Clin Psychiatry 44:79-81.
25. Shardlow CE, Generaux GT, MacLauchlin CC, Pons N, Skordos KW, and Bloomer JC (2011) Utilizing drug-drug interaction prediction tools during drug development: enhanced decision making based on clinical risk. Drug Metab Dispos 39:2076-2084.
26. Smith DA and Obach RS (2009) Metabolites in safety testing (MIST): considerations of mechanisms of toxicity with dose, abundance, and duration of treatment. Chem Res Toxicol 22:267-279.
27. Smith DA and Obach RS (2010) Metabolites: have we MIST out the importance of structure and physicochemistry? Bioanalysis 2:1223-1233.
28. Tornio A, Niemi M, Neuvonen M, Laitila J, Kalliokoski A, Neuvonen PJ, and Backman JT (2008) The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo. Clin Pharmacol Ther 84:403-411.
29. Varma MVS, Lai Y, Kimoto E, Goosen TC, El-Kattan AF, and Kumar V (2013) Mechanistic modeling to predict the transporter- and enzyme-mediated drug-drug interactions of repaglinide. Pharm Res 30:1188-1199.
30. Vishwanathan K, Babalola K, Wang J, Espina R, Yu L, Adedoyin A, Talaat R, Mutlib A, and Scatina J (2009) Obtaining exposures of metabolites in preclinical species through plasma pooling and quantitative NMR: addressing metabolites in safety testing (MIST) guidance without using radiolabeled compounds and chemically synthesized metabolite standards. Chem Res Toxicol 22:311-322.
31. Walsky RL and Obach RS (2004) Validated assays for human cytochrome P450 activities. Drug Metab Dispos 32:647-660.
32. Wrighton SA, Schuetz EG, Thummel KE, Shen DD, Korzekwa KR, and Watkins PB (2000) The human CYP3A subfamily: practical considerations. Drug Metab Rev 32:339-361.
33. Rowland Yeo K, Jamei M, Yang J, Tucker GT, and Rostami-Hodjegan A (2010) Physiologically based mechanistic modelling to predict complex drug-drug interactions involving simultaneous competitive and time-dependent enzyme inhibition by parent compound and its metabolite in both liver and gut - the effect of diltiazem on the time-course of exposure to triazolam. Eur J Pharm Sci 39:298-309.
34. Yeung CK, Fujioka Y, Hachad H, Levy RH, and Isoherranen N (2011) Are circulating metabolites important in drug-drug interactions?: Quantitative analysis of risk prediction and inhibitory potency. Clin Pharmacol Ther 89:105-113.
35. Yu H and Tweedie D (2013) A perspective on the contribution of metabolites to drug drug interaction potential: the need to consider both circulating levels and inhibition potency. Drug Metab Dispos 41:536-540.